# A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

> **NCT01316107** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 122 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ipragliflozin
- **DRUG:** nateglinide

## Key facts

- **NCT ID:** NCT01316107
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-15
- **Primary completion:** 2012-10-19
- **Final completion:** 2012-10-19
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316107, "A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01316107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*